Dr Lal PathLabs Ltd Stock Price Today (NSE: LALPATHLAB)
Fundamental Score
Dr Lal PathLabs Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Dr Lal PathLabs Ltd share price today is ₹1312.10, down 0.17% on NSE/BSE as of 30 March 2026. Dr Lal PathLabs Ltd (LALPATHLAB) is a Large-cap company in the Healthcare Service Provider sector with a market capitalisation of ₹25.56K (Cr). The 52-week high for LALPATHLAB share price is ₹3540.00 and the 52-week low is ₹1272.60. At a P/E ratio of 47.83x, LALPATHLAB is currently trading above its industry average P/E of 39.28x. The company has a Return on Equity (ROE) of 24.30% and a debt-to-equity ratio of 0.07.
Dr Lal PathLabs Ltd Share Price Chart — NSE/BSE Historical Performance
Returns & Performance
ROE
ROCE
OPM (5Y)
Div Yield
Dr Lal PathLabs Ltd Valuation Check
P/E Ratio
Industry P/E
Market Cap
Growth Engine
Profit Growth (Q)
Sales Growth (Q)
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Balance Sheet Health
Debt to Equity
Int. Coverage
Free Cash Flow (5Y)
Shareholding
Promoter
FII
DII
Pledged
Institutional Deep-Dive
Bull Run Research Hub
Dr Lal PathLabs Share Price Analysis: ROCE Efficiency Audit
Within the Healthcare Service Provider industry, a significant challenge lies in balancing rapid expansion with maintaining consistent profitability, especially considering the capital-intensive nature of diagnostic infrastructure. This analysis examines Dr Lal PathLabs Ltd, focusing on its Return on Capital Employed (ROCE). The current Dr Lal PathLabs share price stands at ₹1443.400024, with a Price-to-Earnings (PE) ratio of 47.83 and a ROCE of 28.88%. This analysis is part of a comprehensive 80-parameter fundamental audit verified by Sweta Mishra.
The relatively high PE ratio of 47.83 suggests that the market has strong expectations for Dr Lal PathLabs' future earnings growth. The crucial factor driving this expectation is arguably the company's impressive ROCE of 28.88%. A high ROCE indicates that the company is efficiently utilizing its capital to generate profits. This efficiency allows Dr Lal PathLabs to reinvest earnings strategically, fueling further expansion and potentially strengthening its competitive position within the diagnostic services market. A sustainable, high ROCE forms a crucial element of the company's economic moat.
The 28.88% ROCE directly impacts the company's moat by facilitating several key advantages. Firstly, it allows Dr Lal PathLabs to invest more aggressively in cutting-edge technology and infrastructure, attracting both patients and top talent. Secondly, it provides the financial flexibility to expand geographically, establishing a wider network of collection centers and laboratories. Thirdly, the high returns enable strategic acquisitions that can further consolidate market share and enhance service offerings. These factors collectively contribute to a stronger, more defensible market position.
Comparing Dr Lal PathLabs Ltd with peers is crucial for contextual understanding. While a detailed comparison requires further investigation, we can consider
Suraksha Diagnostic Ltd. A key differentiator might lie in management quality. Efficient capital allocation, as reflected in the superior ROCE, could suggest a more effective management team at Dr Lal PathLabs compared to peers, potentially translating to sustained outperformance. This observational analysis highlights the importance of ROCE as a key indicator of financial health and competitive advantage within the diagnostic services sector.Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Dr Lal PathLabs Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of LALPATHLAB across key market metrics for learning purposes.
Positive Indicators
12 factors identified
Strong Return on Equity (24.30%)
Observation: Efficient use of shareholders' capital generating superior returns.
Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.
Excellent ROCE Performance (28.88%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.
Strong Operating Margins (26.94%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Consistent Growth Track Record (13.09% CAGR)
Observation: Strong 5-year sales compound annual growth rate.
Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model.
Excellent EPS Growth (16.63% CAGR)
Observation: Outstanding 5-year earnings per share compound growth.
Analysis: EPS CAGR >15% indicates strong wealth creation potential.
Strong Profit Growth Track Record (16.69% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model.
Conservative Debt Levels (D/E: 0.07)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Interest Coverage (35.16x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Strong Cash Generation (₹1717.61 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Balanced Promoter Holding (53.21%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Strong Institutional Confidence (FII+DII: 40.08%)
Observation: Significant professional investor participation.
Analysis: High institutional holding often signals thorough due diligence.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
1 factors identified
Premium Valuation Risk (P/E: 47.83x)
Observation: High valuation multiples may limit upside potential.
Analysis: Elevated P/E ratios require strong growth execution to justify current valuations.
Dr Lal PathLabs Ltd Financial Statements
Comprehensive financial data for Dr Lal PathLabs Ltd including income statement, balance sheet and cash flow
About LALPATHLAB (Dr Lal PathLabs Ltd)
Dr Lal PathLabs Ltd is a prominent healthcare service provider specializing in diagnostic and related healthcare tests. With a long-standing reputation built over decades, the comp...any serves as a crucial bridge between medical professionals and patients, offering a comprehensive suite of diagnostic services. Their network encompasses a broad spectrum of tests, from routine blood work to sophisticated genetic and molecular analyses, all performed within state-of-the-art laboratory environments. Leveraging advanced technology and stringent quality control measures, Dr Lal PathLabs provides accurate and timely results that are essential for informed clinical decision-making, aiding in the diagnosis, treatment, and monitoring of various health conditions. The company's operational capabilities extend beyond conventional diagnostics, encompassing specialized testing in areas such as infectious diseases, oncology, and reproductive health. These advanced services cater to the increasing demand for personalized medicine and precision diagnostics, empowering clinicians with insights crucial for tailoring treatments to individual patient needs. Dr Lal PathLabs consistently invests in research and development to stay at the forefront of diagnostic innovation, ensuring that their test menu reflects the latest advancements in medical science. Moreover, their commitment to accessibility is reflected in a widespread network of collection centers, making diagnostic services readily available to a diverse population across geographical regions. Beyond their core testing services, Dr Lal PathLabs also contributes to healthcare advancement through training and educational initiatives. They offer programs aimed at enhancing the skills and knowledge of healthcare professionals, particularly in areas related to phlebotomy and laboratory techniques. This commitment to professional development strengthens the broader healthcare ecosystem, ensuring a skilled workforce capable of delivering high-quality diagnostic services. By combining cutting-edge technology, a comprehensive test menu, and a dedication to professional training, Dr Lal PathLabs plays a vital role in promoting health and well-being within the communities they serve.
Company Details
Key Leadership
Corporate Events
LALPATHLAB Share Price: Frequently Asked Questions
What is the current share price of Dr Lal PathLabs Ltd (LALPATHLAB)?
As of 30 Mar 2026, 12:04 pm IST, Dr Lal PathLabs Ltd share price is ₹1312.10. The LALPATHLAB stock has a market capitalisation of ₹25.56K (Cr) on NSE/BSE.
Is LALPATHLAB share price Overvalued or Undervalued?
LALPATHLAB share price is currently trading at a P/E ratio of 47.83x, compared to the industry average of 39.28x. Based on this relative valuation, the Dr Lal PathLabs Ltd stock appears to be Overvalued against its sector peers.
What is the 52-week high and low of LALPATHLAB share price?
The 52-week high of LALPATHLAB share price is ₹3540.00 and the 52-week low is ₹1272.60. These values are updated daily from NSE/BSE price data.
What factors affect the Dr Lal PathLabs Ltd share price?
Key factors influencing LALPATHLAB share price include quarterly earnings growth (Sales Growth: 10.66%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Dr Lal PathLabs Ltd a good stock for long-term investment?
Dr Lal PathLabs Ltd shows a 5-year Profit Growth of 16.69% and an ROE of 24.30%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.07 before investing in LALPATHLAB shares.
How does Dr Lal PathLabs Ltd compare with its industry peers?
Dr Lal PathLabs Ltd competes with major peers in the Healthcare Service Provider. Investors should compare LALPATHLAB share price P/E of 47.83x and ROE of 24.30% against the industry averages to determine competitive standing.
What is the P/E ratio of LALPATHLAB and what does it mean?
LALPATHLAB share price has a P/E ratio of 47.83x compared to the industry average of 39.28x. Investors pay ₹48 for every ₹1 of annual earnings.
How is LALPATHLAB performing according to Bull Run's analysis?
LALPATHLAB has a Bull Run fundamental score of 64.3/100, indicating moderate strength with some areas for improvement. This comprehensive rating is based on 15+ financial parameters.
What sector and industry does LALPATHLAB belong to?
LALPATHLAB operates in the Healthcare Service Provider industry. This classification helps understand the competitive landscape and sector-specific trends affecting Dr Lal PathLabs Ltd share price.
What is Return on Equity (ROE) and why is it important for LALPATHLAB?
LALPATHLAB has an ROE of 24.30%, which indicates excellent management efficiency. ROE measures how efficiently Dr Lal PathLabs Ltd generates profits from shareholders capital.
How is LALPATHLAB debt-to-equity ratio and what does it indicate?
LALPATHLAB has a debt-to-equity ratio of 0.07, which indicates conservative financing with low financial risk.
What is LALPATHLAB dividend yield and is it a good dividend stock?
LALPATHLAB offers a dividend yield of 0.79%, meaning you receive ₹0.79 annual dividend for every ₹100 invested in Dr Lal PathLabs Ltd shares.
How has LALPATHLAB share price grown over the past 5 years?
LALPATHLAB has achieved 5-year growth rates of: Sales Growth 13.09%, Profit Growth 16.69%, and EPS Growth 16.63%.
What is the promoter holding in LALPATHLAB and why does it matter?
Promoters hold 53.21% of LALPATHLAB shares, with 0.00% pledged. High promoter holding often indicates strong management confidence in Dr Lal PathLabs Ltd.
What is LALPATHLAB market capitalisation category?
LALPATHLAB has a market capitalisation of ₹25557 crores, placing it in the Large-cap category.
How volatile is LALPATHLAB stock?
LALPATHLAB has a beta of N/A. A beta > 1 suggests the Dr Lal PathLabs Ltd stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is LALPATHLAB operating profit margin trend?
LALPATHLAB has a 5-year average Operating Profit Margin (OPM) of 26.94%, indicating the company's operational efficiency.
How is LALPATHLAB quarterly performance?
Recent quarterly performance shows Dr Lal PathLabs Ltd YoY Sales Growth of 10.66% and YoY Profit Growth of 16.41%.
What is the institutional holding pattern in LALPATHLAB?
LALPATHLAB has FII holding of 21.86% and DII holding of 18.22%. Significant institutional holding often suggests professional confidence in the Dr Lal PathLabs Ltd stock.